Cellular and Humoral Immunity in Congenital Blood and Bleeding Disorders

Congenital blood and bleeding disorders encompass a range of inherited conditions that affect hematopoiesis, coagulation, and immune function. These disorders often impair both cellular and humoral immunity, leading to increased susceptibility to infections, immune dysregulation, and autoimmunity. Cellular immunity, mediated by T cells, macrophages, and NK cells, is significantly affected in conditions such as severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and sickle cell disease (SCD). Humoral immunity, dependent on B cells and antibody production, is compromised in disorders like common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), resulting in poor immune responses. Additionally, congenital bleeding disorders such as hemophilia and von Willebrand disease (VWD) can trigger immune complications, including inhibitor development and alloimmunization. Therapeutic strategies such as gene therapy, bone marrow transplantation, immunoglobulin replacement, and vaccination aim to mitigate these immune challenges. Understanding the complex interplay between immune dysfunction and congenital blood disorders is essential for optimizing patient management and developing targeted interventions to improve outcomes. Keywords: Congenital blood disorders, Cellular immunity, Humoral immunity, Immunodeficiency, Gene therapy